HIV immune reconstitution syndrome in sub-Saharan Africa

Simple item page
dc.creatorEasterbrook, Philippa J
dc.date2011-12-14T10:04:50Z
dc.date2011-12-14T10:04:50Z
dc.date2008
dc.date.accessioned2018-09-04T12:32:18Z
dc.date.available2018-09-04T12:32:18Z
dc.descriptionEditorial comment
dc.descriptionOver the last 5 years, there has been remarkable progress in providing HAART to patients in developing countries. In sub-Saharan Africa alone, the number receiving antiretroviral therapy (ART) has more than doubled in the last year, from 300 000 to 810 000. It has long been anticipated that with large numbers initiating ART in these settings, HIV immune reconstitution inflammatory syndrome (IRIS) would be a major problem, because of the low CD4 cell count at ART initiation and high underlying prevalence of infections such as Mycobacterium tuberculosis, and Cryptococcus neoformans. Although the phenomenon of IRIS has been extensively described, the impact of IRIS on ART-related outcomes in resourcepoor settings has not been well documented.
dc.identifierEasterbrook, P. (2008). HIV immune reconstitution syndrome in sub-Saharan Africa. AIDS, 22(5)
dc.identifier0269-9370
dc.identifierhttp://hdl.handle.net/10570/248
dc.identifier.urihttp://hdl.handle.net/10570/248
dc.languageen
dc.publisherLippincott Williams & Wilkins
dc.subjectHIV
dc.subjectSub-Saharan Africa
dc.subjectDeveloping countries
dc.subjectCD4 cell count
dc.subjectHAART
dc.subjectAntiretroviral therapy (ART)
dc.subjectMycobacterium tuberculosis
dc.subjectInfectious Diseases
dc.titleHIV immune reconstitution syndrome in sub-Saharan Africa
dc.typeJournal article, peer reviewed
Files
Collections
Dissertation and Thesis